Aptevo Therapeutics Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Aptevo Therapeutics Inc. (APVO) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $541.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-14
- Aptevo Therapeutics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $270.00K, a 1.10% decline year-over-year.
- Aptevo Therapeutics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $271.00K, a 0.73% decline year-over-year.
- Aptevo Therapeutics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $273.00K.
- Aptevo Therapeutics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $273.00K.
- Aptevo Therapeutics Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.09M, a 1.00% decline from fiscal 2024.
- Aptevo Therapeutics Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.10M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $270.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $541.00K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $271.00K 10-Q · filed 2026-05-13 | ||
| 2025-12-31 | $1.09M 10-K · filed 2026-03-26 | ||
| 2025-06-30 | $273.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $546.00K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $273.00K 10-Q · filed 2026-05-13 | ||
| 2024-12-31 | $1.10M 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |